Novartis (NVS) announced the appointment of Mukul Mehta as the Chief Financial Officer, CFO, and a member of the Executive Committee of Novartis, ECN, effective March 16, 2026. Mukul succeeds Harry Kirsch, who has served as CFO since 2013, and will retire from Novartis. Harry will continue in his role as CFO and member of the ECN until March 15, 2026. Mukul brings 20 years of experience at Novartis and was recently appointed to the role of Head of BPA, Digital Finance and Tax, where he will continue until March of next year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- NVS Earnings: NVS Stock Flattens Despite Sales Surge and $10B Buyback Plan
- Novartis: Strong Performance and Strategic Initiatives Justify Buy Rating
- NVS Earnings: NVS Stock Flatlines Despite Healthier Q2 Sales
- Is NVS Stock (NVS) a Buy Ahead of Q2 Earnings?
- Trump says drug tariffs probable by August 1, semis coming soon, Bloomberg says